EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin‐35 Ameliorates Obesity‐Associated Impairment of Endothelium‐Dependent Vasodilation via the STAT3‐MAPK/ERK‐eNOS Signaling Axis

Kai Li iD, Jie Feng iD, Ren Gong iD, Yunman Liu iD, Yanqing Wu iD

Immunity, Inflammation and Disease · 2026-10 · 14 (10)

DOI: 10.1002/iid3.70564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 22.10.2026. Verfasst von Kai Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Nitric Oxide Synthase Type III, STAT3 Transcription Factor, Obesity, Vasodilation. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Jiangxi Province Key Laboratory of Molecular Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity impairs endothelial nitric oxide synthase (eNOS)‐nitric oxide (NO) signaling, triggering chronic inflammation, endothelial dysfunction and defective vasodilation, which drives cardiometabolic diseases. Existing metabolic therapies provide only indirect vascular protection and fail to resolve residual inflammatory‐mediated cardiovascular risk. As an anti‐inflammatory interleukin 12 (IL‐12) family cytokine, interleukin 35 (IL‐35) is suppressed in obesity and exerts vascular protective effects under inflammatory conditions, yet its function and underlying mechanisms in obesity‑related endothelial vasodilator dysfunction remain undefined. Materials and Methods An obese mouse model was established by 8‐week high‐fat diet (HFD) feeding, followed by 4‐week intraperitoneal administration of recombinant mouse IL‐35. Aortic‐ring assays evaluated vasodilatory function. Palmitic acid (PA)‐treated human umbilical vein endothelial cells (HUVECs), recapitulate lipotoxic endothelial injury, were treated with recombinant human IL‐35. Western blotting, immunofluorescence, 4‐amino‐5‐methylamino‐2′,7′‐difluorofluorescein diacetate (DAF‐FM DA) detection and immunoprecipitation‐mass spectrometry (IP‐MS) were applied to detect IL‐35‐subunit (Epstein‐Barr virus‐induced gene 3 [EBI3] and interleukin‐12 subunit alpha [IL‐12A]) levels, eNOS Ser1177 phosphorylation, phosphorylation of mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MAPK/ERK) signaling molecules (cellular rapidly accelerated fibrosarcoma [cRAF], mitogen‐activated protein kinase kinase [MEK], and ERK) and signal transducer and activator of transcription 3 (STAT3) activation, NO production, and eNOS‐binding partners. Rescue assays were performed using Raf or ERK specific inhibitors and STAT3 small interfering RNA (siRNA).

Results

HFD mice displayed reduced aortic endothelial EBI3 expression, impaired endothelium‐dependent vasorelaxation, decreased eNOS Ser1177 phosphorylation and lowered NO production; all these phenotypes were rescued by exogenous IL‐35. IP‐MS and immunoblotting demonstrated that IL‐35 strengthened eNOS‐ERK1 interaction and restored PA‐repressed phosphorylation of cRAF, MEK, ERK and eNOS Ser1177, which were abrogated by Raf or ERK blockade. Furthermore, IL‐35 recovered STAT3 phosphorylation suppressed by PA, while STAT3 knockdown blunted IL‐35‐driven MAPK/ERK activation, eNOS phosphorylation and subsequent NO production.

Conclusion

IL‐35 alleviates obesity‐induced impairment of endothelium‐dependent vasodilation via the STAT3‐MAPK/ERK‐eNOS axis, which elevates eNOS Ser1177 phosphorylation and NO synthesis. This work supports IL‐35 as a prospective therapeutic candidate for obesity‐associated vascular complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nitric Oxide Synthase Type IIISTAT3 Transcription FactorObesityVasodilationInterleukinsEndothelium, VascularMAP Kinase Signaling SystemAnimalsHumansMiceMaleHuman Umbilical Vein Endothelial CellsDiet, High-FatMice, Inbred C57BLSignal TransductionDisease Models, Animal

Stichwörter der Autor:innen

IL‐35MAPK/ERK signaling pathwaySTAT3endothelial dysfunctionobesity

Substanzen

Nitric Oxide Synthase Type IIISTAT3 Transcription FactorInterleukinsinterleukin-35, mouseStat3 protein, mouse

Autor:innen und Institutionen

  • Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

ORCID-Profile: Kai Li, Jie Feng, Ren Gong, Yunman Liu, Yanqing Wu

Förderung

  • the National Natural Science Foundation of China
  • Jiangxi Province Key Laboratory of Molecular Medicine

Zitieren

APA

Li, K., Feng, J., Gong, R., Liu, Y., & Wu, Y. (2026). Interleukin‐35 Ameliorates Obesity‐Associated Impairment of Endothelium‐Dependent Vasodilation via the STAT3‐MAPK/ERK‐eNOS Signaling Axis. Immunity, Inflammation and Disease, 14(10). https://doi.org/10.1002/iid3.70564

Vancouver

Li K, Feng J, Gong R, Liu Y, Wu Y. Interleukin‐35 Ameliorates Obesity‐Associated Impairment of Endothelium‐Dependent Vasodilation via the STAT3‐MAPK/ERK‐eNOS Signaling Axis. Immunity, Inflammation and Disease. 2026;14(10). doi:10.1002/iid3.70564

BibTeX
@article{Li2026,
  author = {Li, Kai and Feng, Jie and Gong, Ren and Liu, Yunman and Wu, Yanqing},
  title = {Interleukin‐35 Ameliorates Obesity‐Associated Impairment of Endothelium‐Dependent Vasodilation via the STAT3‐MAPK/ERK‐eNOS Signaling Axis},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {10},
  doi = {10.1002/iid3.70564}
}
Kostenlos starten →